Big Pharma / Branded Drugs

Large research-based pharmaceutical companies that discover, develop, manufacture, and sell branded small-molecule drugs and biologic therapies globally. Revenue is concentrated in a small number of high-margin branded products with finite patent-protected lives, recognized net of an unusually large gross-to-net (rebate, chargeback, Medicaid/Medicare, 340B, return, cash discount) deduction stack t

Each company on its own headline number

Ticker	Company	Their metric	Period	YoY	A year ago
VTRS	Viatris Inc.	New product revenue	FY2026-Q2	+27.8%	-62.4%
OGN	Organon & Co.	Renflexis	FY2026-Q2	+3.2%	-8.7%
GILD	Gilead Sciences, Inc.	Biktarvy United States treatment market share	FY2026-Q1	+1.0 pts	+2.0 pts
AMGN	Amgen Inc.	Capital Expenditures	FY2026-Q1	+75.0%	+100.0%
BMY	Bristol-Myers Squibb Company	Camzyos patients on commercial drug	FY2025-Q3	+72.0%	+134.3%

Where they use the same metric

• Adjusted Diluted Earnings Per Share — reported by 8 of 29
• KEYTRUDA Sales — reported by 5 of 29
• Non-GAAP net income — reported by 5 of 29
• Adjusted Gross Margin — reported by 3 of 29

A side-by-side appears only when three or more companies report the same metric in the same unit under their own definition. Companies are listed in value order, not ranked: whether a higher number is better is not asserted.